01—Abstract
Summary
Summary of the 10-K filed March 9, 2006. Cited figures are marked; the original filing is the authoritative source.
Exelixis, Inc. (filed under its then-name, shown in the filing as Exelixis, Inc.) reported a 2005 net loss of $84.4 milliona, down from $137.2 million in 2004, on total revenues of $76.0 million versus $52.9 million in 2004.
Revenue growth was driven largely by a $21.1 millionb recognition tied to the termination of the Genoptera collaboration with Bayer, and by 2005 milestones from GlaxoSmithKline. Research and development expense was $141.1 million and general and administrative expense was $27.7 million. The accumulated deficit reached $603.8 million, and stockholders' equity fell to $33.5 million from $50.7 million at year-end 2004.
The company stated that cash, cash equivalents, marketable securities, investments held by Symphony Evolution, Inc. and restricted cash totaled $210.5 millionc at December 31, 2005. Management expects these resources, together with committed SEI financing and other expected collaborator funding, to sustain operations for at least the next 12 months. That estimate includes repayment of a $30.0 million convertible note to Protein Design Labs due in May 2006.
The GlaxoSmithKline loan agreement carries financial covenants requiring working capital of at least $25.0 milliond and cash and investments of at least $50.0 million, and outstanding borrowings and accrued interest under it totaled $91.8 million. The pipeline spans eight clinical compounds and six preclinical compounds. XL119 is in a Phase 3 trial for bile duct tumors, now managed by licensee Helsinn, and XL999 is in six Phase 2 trials.
Several compounds were out-licensed in 2005 and late 2005, including XL647, XL999 and XL784 to Symphony Evolution, Inc., XL335 to Wyeth and EXEL2255 to Bristol-Myers Squibb. The company stated it is not party to any material legal proceedings.
02—Key points
Key Highlights
- Net loss narrowed to $84.4 million in 2005 from $137.2 million in 2004, while total revenues rose to $76.0 million from $52.9 million.
- Revenue growth was boosted by $21.1 million recognized from the termination of the Genoptera collaboration with Bayer in 2005.
- Cash, cash equivalents, marketable securities and related investments totaled $210.5 million at December 31, 2005, with the company expecting these to fund operations for at least 12 months.
- Accumulated deficit reached $603.8 million and total stockholders' equity declined to $33.5 million from $50.7 million.
- Symphony Evolution, Inc. agreed to invest up to $80.0 million to fund clinical development of XL784, XL647 and XL999, with Exelixis holding purchase and program options to reacquire them.
- New 2005 collaborations included Genentech (upfront license payment, $16.0 million research funding), Helsinn (XL119 license, $4.0 million upfront), Wyeth (FXR license, $10.0 million upfront) and Bristol-Myers Squibb (LXR collaboration, $17.5 million upfront).
- Management stated it will need additional funding to support its development pipeline and that the GlaxoSmithKline loan covenants and the Protein Design Labs note maturing in May 2006 are key liquidity considerations.
03—Questions
Frequently Asked Questions
How much cash did Exelixis have at the end of 2005 and how long is it expected to last?
As of December 31, 2005, cash and cash equivalents, marketable securities, investments held by SEI, and restricted cash and investments totaled $210.5 million. The company anticipates this, along with committed SEI financing and other expected collaborator funding, will enable operations for at least the next 12 months, including repayment of a $30.0 million convertible note due May 2006.
Why did revenue increase so significantly in 2005?
Total revenues rose to $76.0 million from $52.9 million. The filing attributes much of the increase to $21.1 million recognized in connection with the termination of the Genoptera collaboration, along with $5.1 million in revenue from two GlaxoSmithKline milestones and increased research funding from GlaxoSmithKline and Genentech.
What are the main financial covenant risks?
The GlaxoSmithKline loan and security agreement requires working capital of at least $25.0 million and cash and investments of at least $50.0 million. As of December 31, 2005, working capital was $101.6 million and cash and investments were $210.5 million. Outstanding borrowings and accrued interest under the agreement totaled $91.8 million, and a default could allow GlaxoSmithKline to accelerate repayment.
What is the status of the lead clinical programs?
XL119 is in a multi-national Phase 3 trial for bile duct tumors, with management and costs transferred to licensee Helsinn in January 2006. XL999 is in six Phase 2 trials initiated in December 2005. XL647 Phase 2 trials are expected to begin in mid-2006, and XL784 Phase 2 is expected to start in the first half of 2006.
04—Continue